|
Back to Home » March 2021 News » Phase 3 Trial Shows REGEN-COV™ (casirivimab with imdevimab) Antibody Cocktail Reduced Hospitalization or Death by 70% in Non-hospitalized COVID-19 Patients |
Phase 3 Trial Shows REGEN-COV™ (casirivimab with imdevimab) Antibody Cocktail Reduced Hospitalization or Death by 70% in Non-hospitalized COVID-19 Patients |
March 23, 2021
TARRYTOWN, N.Y., March 23, 2021 /PRNewswire/ -- REGEN-COV also significantly shortened the duration of symptoms by 4 days All doses (8,000 mg, 2,400 mg and 1,200 mg) had similar efficacy across all endpoints Companion dose-ranging Phase 2 trial showed significant and comparable viral...
Source URL: https://www.prnewswire.com:443/news-releases/phase-3-trial-shows-regen-cov-casirivimab-with-imdevimab-antibody-cocktail-reduced-hospitalization-or-death-by-70-in-non-hospitalized-covid-19-patients-301253401.html
|
|
|
|
